This review examines the impact of obesity on the pathophysiology of heart failure with
preserved ejection fraction (HFpEF) and focuses on novel mechanisms for HFpEF …

Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable
heterogeneity in both phenotypic and pathophysiological features, with a growing incidence …

Heart Failure with Preserved Ejection Fraction (HFpEF) is one of the most frequent causes of
heart failure in the world's population (about 19–55%), and is commonly associated with a …

Background: The relationship between serum glucose/potassium ratio (GPR) and the
adverse outcomes in patients with heart failure with preserved ejection fraction (HFpEF) has …

Cardiovascular disease (CVD) stands as a predominant global cause of morbidity and
mortality, necessitating effective and cost-efficient therapies for cardiovascular risk reduction …

Some glucagon-like peptide-1 receptor agonists (GLP-1 RAs), first used in the treatment of
type 2 diabetes mellitus (T2DM), have been approved for the treatment of obesity in patients …

Background There is uncertainty with respect to the baseline tumor markers and clinical
outcomes for patients with connective tissue disease-associated interstitial lung disease …

Background and Objective About half of all heart failures are heart failures with preserved
ejection fraction (HFpEFs). As the population ages and metabolic disorders become more …

The majority of cyanotic congenital cardiac defects are caused by the tetralogy of Fallot.
Some symptoms include a biventricular connection of the aortic root, right ventricular …

Heart failure (HF) is one of the most strongly associated adverse cardiovascular events
linked to the use of cyclooxygenase (COX)-2 selective and non-selective nonsteroidal anti …